-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Sanara MedTech to Neutral, Lowers Price Target to $35

Benzinga·07/30/2026 11:15:35
Listen to the news
HC Wainwright & Co. analyst Yi Chen downgrades Sanara MedTech (NASDAQ:SMTI) from Buy to Neutral and lowers the price target from $36 to $35.